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Take Home Messages:  
− PBM prescription claims data are often implictly assumed to be complete 
− PBM data are used to measure exposure to prescription drugs in many observational studies 
− 93% of PBM derived pharmacy claim records were source verified with pharmacy provider records 
− PBM benefit features were not consistently related to persons with missing PBM records 
− There was wide variability between therapeutic classes with regard to missing PBM records 
 
Abstract 
Objectives:  To determine if and to what extent records obtained from PBM pharmacy claims differ from source documents obtained 
directly from pharmacy providers.  This study also sought to explore possible associations between patient, pharmacy benefits, and 
pharmacy provider characteristics and the likelihood a patient would have missing prescription claims.  
Methods: This study used a cross-sectional  design which included  a sample of 1,484 patients residing in a single state with a 
common pharmacy benefit.  Profiles describing all prescriptions filled in a pharmacy between January 1, 2002 through June 30, 2002 
of these patients were requested directly from their pharmacy providers.  Logistic regression was used to explore the factors 
associated with a person receiving a prescription that did not appear on the PBM claims.  
Results:  Of the 1,484 eligible recipients sampled,  profiles were obtained for 323 (22%) persons and there were analyzable profiles 
for 315 (21%) persons.  There were a total of 2,977 prescriptions filled for the 315 subjects.  Of  those 2,977 prescriptions, 207 (7.0%) 
were missing from the claims files indicating that 93% were captured. Only prescription volume consistently influenced the likelihood 
a patient would have a missing prescription from the PBM claims (OR =1.08; 95%CI:1.05-1.12). 
Conclusion: Claims obtained from pharmacy benefit companies capture approximately 93% of prescription records when verified with 
records obtained from pharmacy providers.  The rate of missing records from PBM claims does not appear to be meaningfully 
influenced by most finance based pharmacy benefit design features. However, certain classes of drugs such as iron products, 
digoxins, diuretics, sulfonylureas, and antigout may have incomplete claims records compared to other classes of drugs.  Higher 
prescription utilizers are more likely to have prescription records filled that are not captured by PBMs.  These conclusions should be 
interpreted in light of the modest usable response rate from pharmacy providers of 22% and the unknown generalizability of these 
patients utilizing one particular PBM from 2002 in the state of Georgia. 
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Introduction 
Electronic health claims databases are increasingly being 
utilized to conduct a wide range of epidemiologic, safety, 
economic, and health policy investigations.  Prescription 
claims records are a key component to many of these types  
of observational studies.  In epidemiologic and safety 
investigations, prescription claims are often used as the sole 
measure of 'exposure' to determine both the presence or 
absence of drug exposure as well as the intensity of exposure 
(dosage, duration, quantity).  In economic and health policy 
investigations, prescription drug claims are used to define 
treatment groups for cost comparison and outcomes studies 
and they are an important component of the total health care 
costs.1-6 Prescription claims database have also been used as 
a standard to compared the validity of other drug exposure 
sources such as self-reported drug use, however, the sources 
to assess drug exposure have potential for inaccuracies.7, 8  
 
Prescription claims records are the electronic artifacts 
documenting the financial transactions between patients, 
pharmacy providers and health care payers.  The electronic 
records generated from these transactions typically include 
patient, drug, and payment information that can be used 
alone or linked by patient identifier with other medical claims 
or clinical information systems for research purposes.9  In the 
U.S., pharmaceutical benefit managment companies (PBMs) 
serve as the fiscal intermediary between pharmacy provider 
and health payers and the ten largest PBMs provided benefits 
for over 700 million persons in the U.S. in 2011.10, 11  Because 
of their sheer size, the electronic prescription claims data 
derived from PBMs are one of the most common sources of 
prescription drug information used for retrospective 
pharmacoepidemiologic research.12        
 
Prescription claims files are frequently used for research 
purposes  and the accuracy of these prescription claims to 
measure cost or exposure is largely unknown.  Despite the 
financial incentives for pharmacists to submit prescription 
claims to a PBM, there are many reasons why this may not 
occur thus circumventing the capture of the electronic 
prescription record.  Some of those reasons might be: the 
drug may cost less than the amount of a copay, the 
prescription may be for a non-covered item or requires prior 
authorization, the persons may want to protect their 
confidentiality, persons may have exceeded a cap or 
maximum limit, or persons may be enrolled in two or more 
insurance plans.  When prescription claims records are not 
complete, there is a fundamental measurement bias which 
may result in case ascertainment bias, exposure 
misclassification biases, or systematic underestimation of 
prescription utilization and costs. 12-14    
  
To date, there is little evidence empirically testing this 
assumption.  There have been indirect assessments of 
accuracy of prescription claims by comparing drug 
compliance measures using pharmacy claims data with other 
compliance measures including patient self-reported 
measures15, 16  and studies testing the accuracy of 
prescription claims information to define or supplement case 
definitions for hypertension.17   Direct assessments of the 
validity of prescription claims comparing prescription claims 
with other medical data, such as a patients chart, have 
generally been performed in narrow populations or for 
selected drug classes and the results have been highly 
variable.8, 13, 18-23   
 
Another approach to assess the accuracy of prescription 
claims files would be to compare the prescription claims 
records with pharmacy provider profiles.  This approach has 
decided advantages over comparisons with medical charts 
and patient information since pharmacy records are 
maintained in electronic and paper forms. Also, the pharmacy 
profiles represent medications that were picked up at the 
pharmacy rather than those for which a prescription was 
written which may or may not have ever been filled.  
Furthermore, the pharmacy records of pharmacy providers 
have been found to be a reliable source to determine the 
drug exposure when compared to patient self report.24-26  
There have been two U.S. Medicaid based studies and one 
Canadian study comparing prescription records to electronic 
claims files.3, 27, 28 However, two of these studies were 
conducted in government payer systems which provide 
benefits to the poorest patients and we do not know the 
accuracy of these claims for commercial populations,3, 27 and 
the other focused on prescriptions that were abandoned or 
refilled but did not validate the PBM records.29    
 
The overarching goal of this study was to address this 
information gap by assessing the validity of electronic 
prescription claims records for persons with commercial 
pharmacy benefits in the U.S.  More specifically, the objective 
of this study is to determine if and to what extent records 
obtained from PBM pharmacy claims differ from source 
documents obtained directly from pharmacy providers.  Also, 
this study sought to explore possible associations between 
patient characteristics (gender, age), pharmacy benefit 
characteristics (copay amount, 2 / 3 tier copay structure, 
deductible, coinsurance), or pharmacy provider 
characteristics (chain / independent) which influences the 
likelihood a patient would have missing prescription claims 
from the PBM electronic prescription claims records. 
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Methods 
Study Design 
This study used a cross-sectional study design.  The general 
framework was to sample patients residing in a single state 
with a common pharmacy benefit from one of the nation’s 
largest PBMs, Express Scripts Inc., and survey their pharmacy 
providers and request that they return patient profiles 
(record of all prescriptions dispensed) for those persons with 
patient identifiers removed.  Prescription records obtained 
from the pharmacy providers were then linked by encrypted 
patient identifier to the prescription records obtained from 
the PBM and compared.    
 
Sample and Data Collection 
Recipients were identified by searching the PBM’s recipient 
data of over 44,000 commercial persons eligible for pharmacy 
benefits in Georgia.  The following inclusion and exclusion 
criteria were applied to identify eligible recipients: 
 
1. Continuously eligible for pharmacy benefits from 
January 1, 2002 through June 30, 2002.                                                                                                         
2. At least 18 years of age on January 1, 2002 
3. Had pharmacy claims from no more than one 
pharmacy store during the study period.  
4. Resided and utilized pharmacies in Georgia.  
5. Had a rider in their pharmacy benefit contract that 
permitted the PBM to conduct research using their 
pharmacy data. 
6. Exclude members with HIV or antipsychotic 
prescription claims 
7. Exclude persons with mail order claims 
8. Exclude persons with member submitted claims 
 
These criteria were utilized to minimize the chances of 
persons utilizing pharmacies not sampled and to exclude 
patients that may have obtained their prescriptions from 
charity or public health clinics (HIV and antipsychotic users).  
After applying the inclusion and exclusion criteria, 21,303 
subjects were eligible to participate.  From the eligible pool of 
recipients, subjects were randomly chosen within plan 
features (3-tier copay, 2-tier copay, coinsurance, and 
deductibles) so that those with less common prescription 
plan features (coinsurance and deductible) would be 
adequately represented.  Due to budgetary considerations 
and the sampling scheme to identify recipients with all plan 
features, 1,771 subjects were randomly selected.  Each 
subject’s pharmacy provider was identified, and each 
pharmacy was mailed a letter requesting prescription profiles 
to be returned for the subjects identified in the sample that 
utilized their pharmacy.  There were 818 pharmacies in the 
initial sample that provided pharmacy services for the 1,771 
selected subjects.  The letter contained instructions 
requesting the pharmacist to return pharmacy profiles 
containing all prescriptions filled during the study period from 
January 1, 2002 through June 30, 2002 in a pre-paid postage 
envelope.  The patient profiles requested were typical print 
outs that patients routinely ask their pharmacists to prepare 
for them for tax and/or insurance purposes. Pharmacists 
were provided with the recipient name and date of birth, so 
that they could identify the sample persons. The pharmacists 
were then instructed to de-identify the prescription records 
and to place an encrypted identifier on the prescription 
profile so that the records could be later linked to the PBM 
claims data.  The pharmacy letter was initially mailed out on 
December 2002, and there was a follow-up reminder post 
card mailed approximately 6 weeks after the initial mailing.  
All the patient prescription records were entered into a 
relational database by trained, blinded data entry personnel 
who had retail pharmacy experience.  The data entry 
personnel were blinded in the sense that they had no access 
to the PBM claims information and could not be influenced 
by those records when keying records from the pharmacy 
profiles.  Key fields (encrypted ids, NDC numbers and dates or 
prescription fill) were double keyed entered.  After the 
pharmacy profile records were linked to the PBM records by 
encrypted ID, date, and NDC number, those keyed records 
that were discordant were identified and verified with source 
documentation.  Initially there were 542 discordant 
prescription records.  Corrections to the pharmacy profile 
data were made by inspecting the source records and keying 
errors were fixed.  Also, NDC codes were set to match claims 
file for 79 profile records when the same drug was dispensed 
on the same day for the same patients as indicated from the 
claims, but had an NDC code that did not match the claims.  
For example, drugs subject to MAC (Maximum Allowable 
Costs) pricing may have different NDC codes on the claims file 
for multi-source products such as acetaminophen and 
hydrocodone.   
 
All prescriptions were merged with Multum therapeutic 
classifications (http://www.multum.com) and supplemented 
with a PBM supplied therapeutic classification for 
prescription NDCs that could not be matched with Multum 
therapeutic classes.  Those records that did not appear in the 
PBM claims files (prescriptions exclusively from pharmacy 
profiles) were merged with a file supplied by the PBM 
describing the Drug Utilization Review (DUR) edits and rejects 
which provide some details on why a claim was not 
reimbursed by the PBM.   
 
To account for the oversampling of persons with certain 
pharmacy design features, sample weights were derived from 
the posterior probabilities of being selected into the sample.  
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For example, all 272 (100%) persons in the eligible population 
that had a coinsurance were selected into the sample. 
However, only 5.9% of the eligible population that had a two-
tier benefit were selected into the sample.  Consequently, 
persons with coinsurance were relatively oversampled and 
consequently were assigned a lower sampling weight.  The 
analysis reports the unweighted results as the base case and 
the weighted results are presented when relevant.  
 
This study was approved by the Institutional Review Board 
(IRB) of the University of Georgia Humans Subject Office.  
 
Analysis 
The weighted and unweighted number of prescriptions by 
source (Profile only, PBM only, both) was calculated.  The 
denominator for all calculations was unduplicated 
prescription records irrespective of source (records from both 
the PBM claims and Profiles were only counted as one).   The 
sensitivity and positive predictive value (PPV) of the 
prescription record as a unit of analysis was calculated 
utilizing the pharmacy profile records as a ‘gold-standard’ 
measure.   For each analyzable subject, a patient level file was 
constructed denoting the number of prescriptions filled from 
each source of information.  Utilizing the patient level file, an 
exploratory analysis sought to identify associations between 
patient demographic and pharmacy benefit features and the 
likelihood of obtaining one or more prescriptions that were 
not adjudicated with the PBM.  The variables available guided 
the comparisons and specifically the following variables were 
explored a-priori: age, percent elderly (age > 65 years), 
gender, pharmacy type (Independent vs. Chain), number of 
Rxs, sum paid for all Rxs, presence of a deductible, family 
deductible amount, member deductible amount, presence of 
coinsurance, presence of a three-tier copay, generic copay 
amount, preferred brand copay amount, non-preferred brand 
copay amount.  Univariate associations were explored using 
t-test, approximate t-test with a Satterthwaite correction 
(when variances were not equal), and Chi-square tests.  
Logistic regression using the maximum likelihood method was 
used to obtain adjusted odds ratios of receiving prescriptions 
not adjudicated with the PBM.  To explore some plan 
features, such as the level of copay across tiers, the analysis 
required the subject to be in a tiered plan and not all subjects 
could be included in those analyses which resulted in several 
model specifications to assess each of the plan features. 
 
Results 
A total of 189 pharmacies (23%) responded to the request to 
obtain prescription profiles. Of those, 6 provided unusable 
patient profiles (no dates supplied by one, and three did not 
return encrypted identifiers, one refusal, and one pharmacy 
could not confirm the date of birth) bringing the usable 
response rate to 183 (22%).  These 183 pharmacies provided 
profile information for 363 recipients which represented 20% 
of the original 1,771 sampled recipients. 
 
During the course of the study, it was determined that one 
health plan whose recipients were initially part of the sample 
did not want their members to be included in the study.  This 
health plan had 287 members initially included in the sample.  
After applying this post-hoc exclusion, the initial sample was 
reduced to 1,484 eligible recipients, and the number of 
recipients with a profile decreased to 323 (22%).     
 
Table 1 contains the demographic statistics of the 1,484 
eligible recipients that were surveyed and the 323 with 
profiles returned.   The average age of the sample was about 
46 years and approximately 60% were female. There were no 
statistically significant differences between recipients with a 
pharmacy profile and those without pharmacy profiles  on 
any of the pharmacy benefit features (p>0.05) or 
demographic characteristics.     
 
There were a total of 3,112 prescription records, 3,000 
originated from the pharmacy profiles and 2,880 came from 
the PBM claims for these 323 persons.   Out of 323 persons, 
there were 4 persons who had valid pharmacy profiles 
returned without any prescription records but had 
prescription records on the PBM claims.  There were also an 
additional 4 recipients who had no prescriptions match on 
either profile (100% of prescription records were discordant).  
In both of these circumstances, it appears that despite the 
source verification for these pharmacy profile records, there 
may have been profiles returned for the wrong person or 
there may be errors with the encrypted IDs supplied by the 
PBM.  A post-hoc decision was made to exclude these 
subjects from further analysis resulting in a final sample of 
315 subjects for which there is valid prescription information 
from both the pharmacy profiles and the PBM claims (Figure 
1).  
 
For the final analyzable sample of 315 subjects, there were a 
total of 2,977 prescriptions (9.45 Rxs per person; 1.6 Rxs per 
person per month) filled.  There were only 16 (0.5%) 
prescriptions records that appeared on the PBM claims 
without a corresponding record on the pharmacy profiles 
(Figure 1).   An overwhelming majority (n=2754, 92.5%) of 
prescription records appeared on both the pharmacy and 
PBM prescription sources with the remaining 207 (7.0%) that 
appeared only on the pharmacy profiles corresponding to a 
PPV=99.42% and sensitivity=93.01%.  When the sampling 
weights were used to adjust for the non-random sampling 
procedure, 6.5% of all prescriptions appeared only on the 
pharmacy profiles that were missing from the PBM claims 
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and 0.4% of all prescriptions appeared on the PBM claims 
that were not included on the pharmacy profiles.    
 
The therapeutic classes of the prescriptions that had 5 or 
more prescriptions missing from the PBM claims (identified 
only through the profiles) and the most common therapeutic 
classes are displayed in Figure 2.  Hormones and drugs that 
can be used to treat cardiac conditions and hypertension 
were the most common drugs used by this sample.  
Prescriptions for iron products, inotropics, antigout, loop 
diuretics, and sulfonylureas, were most likely to be missing 
from the PBM claims as 75%, 67%, 42%, 29.4%, and 20% of 
the prescriptions for these therapeutic classes, respectively, 
were not recorded on the PBM claims.   
 
There were 61 persons (19.4%) that had one or more 
prescriptions that were not contained on the PBM 
prescription records.  When sampling weights were used, 
18.2% of persons had one or more prescriptions that were 
not contained on the PBM prescription records.  A majority 
(54.1%) of those persons had just a single prescription that 
was not contained on the PBM claims records (Table 2).  Only 
9 (2.9%) persons had, on average, more than one prescription 
per month (6 in the 6 month study period) filled that was not 
captured on the PBM claims.  The source of payment for the 
prescription records captured exclusively from the pharmacy 
profiles was recorded where possible.  For 77 of the profile 
derived prescription records, the pharmacy profiles were not 
detailed enough to determine the source of payment for 
these records.  For the remaining 130 pharmacy profile 
derived records, there were 97 (74.6%) prescriptions that 
were paid for out of pocket and 33 (25.4%) prescriptions that 
were paid for by a third party other than the PBM (Table 2).   
 
Persons who had missing records from their PBM claims files 
consumed more prescriptions in total and paid more for 
prescriptions over the 6 month period than did persons with 
all their prescriptions contained on the ESI claims (Table 3:  
p<0.0001).  When sampling weights were used, the same 
associations between prescription volume and total 
prescription price were found between persons with missing 
records from the PBM claims (Table 3: p<0.05).  Both the 
weighted and unweighted multivariate results confirmed the 
positive relationship between the total prescription volume 
and the likelihood of having a prescription filled without a 
claim appearing on the ESI prescription records (Table 4).  In 
the unweighted analysis, a one dollar increase in the generic 
copay amount was associated with a 12% increase in odds of 
having at least one prescription not submitted to the PBM. 
However, this relationship was not significant in the weighted 
analysis.  Similar results were obtained with the alternate 
model specifications where those with three tier, two tier, 
deductible and coinsurances were dichotomized including the 
entire sample. 
 
The average amount paid by the patients tended to be higher 
for prescriptions not reimbursed than those prescriptions 
adjudicated with the PBM; but were not significantly different 
unless 2 prescriptions with paid amount > $1,000 were 
excluded ($23.21 vs. $15.92 p=0.0003).  The days supply 
tended to be higher for prescriptions not adjudicated with 
ESI, but the increase of approximately 2 days supply was not 
significant.  There were only 7 prescriptions not adjudicated 
with PBM that had days supply > 31 days.     
 
The DUR edits file identified reasons for 72 prescription 
records that were filled in the pharmacy but not paid for by 
the PBM.  The three most common reasons were: product / 
service not covered, followed by refill too soon, and refills not 
covered.  These three reasons accounted for over 80% of the 
reasons for claim rejects.   
 
Discussion 
This study determined that the two sources of prescription 
information had fairly good agreement as over 90% of 
records from both sources were captured on both the PBM 
claims and the pharmacy profiles which is reflected in very 
high sensitivities and positive predictive values over 90%.  
There are very few occurrences (< 1%) of prescription records 
on the PBM claims that do not appear on the pharmacy 
profiles. However, there is a modest (7%) number of 
prescriptions found only on the pharmacy profiles and not on 
the PBM claims.  These results are similar to other previous 
findings.  A study comparing medical records, pharmacy 
records, and Medicaid prescription claims records for 37 
Medicaid eligible persons found that 93% and 83% of the 
Medicaid prescription records were accurate relative to the 
pharmacy files and medical records respectively.27 Another 
Canadian study comparing Drug Programs Information 
Network in Manitoba found that the accuracy of the claims 
ranged from 80% to 90% depending on the eligibility status of 
the person.28    If one were to use a stricter standard where 
the person is the unit of analysis, nearly 20% of persons had 
one or more prescriptions that did not appear on the PBM 
claims, though a majority of these persons had just a single 
prescription not adjudicated with the PBM over the 6 month 
time horizon.   
 
Unfortunately, there was just one consistent predictor, 
prescription volume, which was more likely to result in 
prescriptions not adjudicated with PBM.  Patients utilizing 
more prescriptions may be just more likely to have missing 
plan information than patients with lower volume of 
prescription, simply due to the fact that they have more 
http://z.umn.edu/INNOVATIONS                        2014, Vol. 5, No. 4, Article 184                        INNOVATIONS in pharmacy   5 
 
Original Research SCIENCE 
 
records that could be missing.  This is corroborated by a study 
of 743 high Medicaid prescription users that found that the 
Medicaid prescription claims were missing for 21% of the 
prescription records obtained directly from pharmacy 
providers.30 The amount of the drug copays and the 
pharmacy type were inconsistent or non-significant 
predictors.  This would suggest that not having a prescription 
claim adjudicated is more or less at random with regard to 
plan and patient characteristics after accounting for the 
number of prescriptions filled.    
 
Despite the overall high rate of concordance between the 
claims and pharmacy profiles, there were several categories 
of drugs with much lower rates of concordance such as 
specialty (uncategorized) prescriptions, OTC Iron products, 
and inotropics (digoxin) in which the PBM claims were 
missing for over 50% of those prescription records.  
Prescriptions for less expensive generic drugs such as 
diuretics, sulfonylureas, and antigout agents were also 
missing from the PBM claims 20-50% of the time.  The 
implications of this finding are that despite the relative 
completeness of the electronic claims files overall, using only 
the electronic claims may substantially underestimate 
exposure to certain classes of drugs, particularly those that 
are inexpensive or not covered on the formulary.  
Unfortunately, the sample sizes of any one therapeutic 
category in this study with the lower concordance rates 
noted is relatively small (n<50) so these results should be 
interpreted with caution.   
 
For an appreciable number of persons with missing 
prescriptions records from the ESI claims, access to multiple 
PBMs which may be obtained through a spouse or parent and 
depending on the benefit structure of the PBM plans 
occurred for at least 18% of the 61 persons with missing 
prescription claims from the PMB.  This is a conservative 
estimate because the source of payment could not be 
obtained from the pharmacy profiles for 77 of the non-ESI 
prescription records.  Another reason to not submit the 
claims to the PBM may be to obtain a greater days supply 
which may be cost saving as well as time saving for the 
patient.  The data in this study do not suggest that this is a 
meaningful concern as only 7 prescriptions out of the 206 
prescriptions had a day’s supply greater than 31 days which is 
a typical limit for many PBM beneficiaries at retail settings.   
 
Limitations 
There were 8 patients that had valid pharmacy profiles 
returned that were excluded post-hoc because they had 
either no pharmacy records on their profile or had absolutely 
no overlap between prescription records the ESI and 
pharmacy profiles.  It is believed that the pharmacy may have 
returned the wrong profile for these patients or there may 
have been some other administrative errors where the 
correct patient could not be linked to the original PBM claims.  
We recognize that by excluding these persons, the rate of 
prescription concordance is higher than would be estimated if 
the records were retained.  A response rate of 22% is modest, 
and it is possible that pharmacy profiles obtained from 
pharmacy providers who responded to the survey may not be 
representative of the whole.  As a check for potential 
response bias, the demographic and pharmacy provider 
characteristics were checked against the whole sample and 
no significant differences were detected, though those with 
deductibles trended towards higher response rates.  Also, the 
sample was not selected completely at random from all PBM 
beneficiaries.  A weighting scheme was used to attenuate the 
non-random sampling and the weighted results are reported 
where relevant and had little impact on the findings in most 
cases.  It should also be noted that patients without any PBM 
claims were not sampled because there was no practical way 
to identify their pharmacy provider and this restriction 
prevented the calculation of other measures of accuracy 
including specificity and negative predictive values.  The 
pharmacy profiles were considered as a gold standard which 
was necessary to calculate sensitivity and positive predictive 
value, but we recognize that all widely used methods to 
assess drug exposure, including pharmacy profiles, may 
misclassify true exposure status.  To protect the patient 
confidentiality and minimize the effort of pharmacists who 
voluntarily participated in this study, no additional patient 
data was sought.  This meant that possible factors, such as 
race, could not be explored in this study.  There are no 
standards for the format or even the minimum content for 
the information supplied on pharmacy profiles.  The 
variability in the pharmacy profiles and the lack of various 
fields in some profiles made it impossible to collect uniform 
prescription information for all prescription records.  This is 
most recognizable when the source of payment is missing for 
77 of the 207 records derived exclusively from the pharmacy 
profiles.  Some pharmacy benefit characteristics such as the 
coinsurance amounts, deductible amounts, or copay 
amounts, could only be assessed in subsets of the entire 
sample (i.e. those with coinsurance or a deductible) which in 
some cases reduced the sample size for those analyses. Since 
the study used data from 2002, the accuracy of more 
contemporary commercial PBM claims may be different 
particularly given the growth of electronic prescribing and $4 
generic programs and the implementation of Medicare Part-D 
benefits.  Lastly, the estimates obtained from this study are 
from a single PBM for recipients in a single state.  To the 
extent the pharmacy benefit designs and population 
characteristics between this population and others differ and 
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influence the estimates obtained herein, our results are 
limited in their generalizability.   
 
Conclusions       
Claims obtained from pharmacy benefit companies capture 
approximately 93% of prescription records when verified with 
records obtained from pharmacy providers.  The rate of 
missing records from PBM claims sources does not appear to 
be meaningfully influenced by most pharmacy benefit design 
features such as deductibles, coinsurance, copays, or tiered 
plans nor most patient characteristics.  Higher prescription 
utilizers are more likely to have prescription records filled 
that are not captured by PBMs than their lower prescription 
utilizing counterparts.   Electronic prescription records may 
be less complete for less expensive generic products and OTC 
products. 
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Table 1.  Demographic and Pharmacy Benefit Statistics for the  
Eligible Sample and Recipients with Their Pharmacy Profile Returned 
 
 
Eligible Sample,  
n=1,484 
           (n)                        (%) 
Recipients with a pharmacy 
profile returned, n=323 
             (n)                     (%) 
 
p-value** 
Female 871 58.69% 195 60.37% 0.4902 
Age (mean / s.d.) 46.6 (14.7) 46.7 (15.1) 0.8553 
Elderly > 65 years 159 10.71% 38 11.76% 0.4884 
      
Coinsurance* 246 16.58% 61 18.89% 0.6365 
Two Tier Copay* 410 27.63% 77 23.84% 0.0851 
Three Tier Copay* 643 43.33% 147 45.51% 0.3709 
Deductible* 246 16.58% 65 20.12% 0.0526 
      
Chain Pharmacy 1236 83.29% 265 82.04% 0.4997 
Independent Pharmacy 248 16.71% 58 17.96% NA 
      
TOTAL 1484 100.00% 323 100.00%  
 
    * members with that pharmacy benefit feature    
** Chi-Square or t-test of difference between recipients with a pharmacy profile and those without a 
pharmacy profile 
 
 
Table 2. Frequency of People by the number of prescriptions per person not captured on PBM claims 
Number 
of Rxs 
Not on 
PBM 
Claims 
 
 
 
Frequency 
of Persons 
 
 
 
% 
 
Number of 
Rxs Paid for 
Out of 
Pocket** 
 
 
 
Frequency of 
Persons 
 
 
 
% 
Number of 
Rxs Paid for 
by Other 3rd 
Party*** 
 
 
 
Frequency 
of Persons 
 
 
 
% 
1 33 54.1% 1 24 57.1% 1 6 54.5% 
2 5 8.2% 2 2 4.8% 2 2 18.2% 
3 4 6.6% 3 7 16.7% 6 1 9.1% 
4 3 4.9% 4 4 9.5% 8 1 9.1% 
5 6 9.8% 5 3 7.1% 9 1 9.1% 
6 1 1.6% 7 1 2.4%    
7 1 1.6% 10 1 2.4%    
8 2 3.3%       
9 1 1.6%       
10 2 3.3%       
13 1 1.6%       
15 1 1.6%       
24 1 1.6%       
         
TOTAL 61 100.0%  42 100.0%  11 100.0% 
 
** Prescriptions where the source of payment could be determined from the pharmacy profile and was known to be paid 
for out of pocket 
*** Prescriptions where the source of payment could be determined from the pharmacy profile and was known to be paid for by 
some other third party 
****source of payment could not be determined for 77 prescriptions records derived exclusively from the pharmacy profiles 
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Table 3. Demographic and Pharmacy Benefit Features of Those 
With and Without Missing Prescription Records from PBM Claims 
 At least One Missing 
Record from PBM 
Claims n= 61 
mean / freq (s.d. / %) 
No Missing Records 
from PBM 
Claims n=254 
mean / freq (s.d. / %) 
 
 
 
p-value 
 
 
weighted*** 
p-value 
Age  48.7 (14.3) 46.3 (15.4) 0.2616 0.4034 
N Elderly (age >65) 9 (14.8%) 29 (11.4%) 0.4724 0.9945 
N Female 37 (60.7%) 153 (60.2%) 0.9525 0.8581 
     
Independent Pharmacy 15 (24.6%) 41 (16.1%) 0.1212 0.1318 
     
Number of Rxs  16.4 (15.0) 7.8 (9.5) <0.0001 <0.0001 
Sum Paid for all Rxs 341.2 (491) 125.0 (162) <0.0001 <0.0001 
     
N with a Deductible 13 (21.3%) 49 (19.3%) 0.7216 0.6302 
Family Deductible Amount $* 34.4 (179) 18.05 (111) 0.3658 0.5706 
Member Deductible Amount $* 27.1 (92.7) 15.7 (59.0) 0.2370 0.3987 
N with Coinsurance 11 (18.0%) 51 (20.1%) 0.7182 0.9687 
N with Two Tier Copay 30 (49.2%) 133 (52.4%) 0.6552 0.6463 
N with Three Tier Copay 31 (50.8%) 121 (47.6%) 0.6552 0.6463 
Generic Copay Amount $ **  11.02 (4.8) 9.59 (4.8) 0.0609 0.0909 
Preferred Brand Copay $ ** 20.84 (9.9) 19.10 (8.1) 0.1967 0.2702 
Non-Preferred Brand Copay $ ** 22.12 (22.1) 19.92 (18.9) 0.4770 0.2548 
 
* includes those with zero values when members do not have a deductible   
** Based only on those without coinsurance (n=253) and includes those with zero values  
*** sample weights derived to account for oversampling of persons with various pharmacy benefit features  
     and significant differences are of the same direction as the unweighted analysis unless otherwise noted 
 
 
 
 
Table 4. Multivariate Adjusted Odds Ratios of Factors Potentially 
Associated with Obtaining Prescriptions not on PBM Claims 
 
Parameter 
Unweighted n=253 
Odds Ratio               95% CI 
Weighted = 253 
Odds Ratio                   95% CI 
Age (yrs) 0.983 0.956 1.011 0.978 0.951 1.005 
Gender (f=1) 0.814 0.400 1.654 0.809 0.407 1.611 
Pharmacy Type (Chain=1) 0.915 0.392 2.135 0.775 0.353 1.704 
Sum Prescriptions Filled 1.084 1.047 1.123 1.081 1.051 1.113 
Deductible 1.003 0.433 2.322 1.070 0.333 3.435 
Generic Copay Amount 1.116 1.002 1.244 1.120 0.989 1.270 
Non-Preferred Brand Copay 0.996 0.978 1.015 1.003 0.983 1.024 
Preferred Brand Copay 1.000 0.940 1.065 1.002 0.930 1.080 
 
    Model C-statistic 0.746   0.732 
    Prob. > Wald Chi-Square  0.0004   <0.0001 
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Table 5. Alternate Model with Coinsurance Status included and Copay Amounts Excluded 
 
 
Parameter 
      Unweighted n=315 
  Odds Ratio              95% CI 
       Weighted = 315 
   Odds Ratio           95% CI 
Age (yrs) 0.993 0.971 1.016 0.980 0.954 1.006 
Gender (f=1) 0.783 0.423 1.449 0.756 0.391 1.463 
Pharmacy Type (Chain=1) 0.704 0.342 1.45 0.781 0.365 1.670 
Sum Prescriptions Filled 1.064 1.035 1.093 1.073 1.045 1.103 
Deductible   1.016 0.480 2.152 1.257 0.426 3.710 
Three Tier Plan 1.038 0.525 2.053 0.978 1.110 2.154 
Coinsurance 0.712 0.276 1.838 0.978 0.138 6.942 
 
    Model C-statistic 0.733   0.714   
    Prob. > Wald Chi-Square  0.0014   0.0001   
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Figure 1. Steps to obtain the study population and source of prescription records 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Study population 
-  - - - - - - - - - - -  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 Source of prescription records             Total number of prescription records=2,977 
 
 
 
 
 
          PBM only     PBM and pharmacy  Pharmacy only 
         16 (0.5%)          2754 (92.5%)                     207 (7.0%) 
 
 
 
 
 
  
Subjects who met the inclusion exclusion criteria 
(21,303) 
 
 
Number of subjects randomly selected for the study  
(1,771) 
 
 
Number of subjects with pharmacy profile information  
(363) 
 
 
Number of subjects after post-hoc exclusion  
(323) 
 
 
Number of subjects after excluding those who had no 
prescriptions records in pharmacy (319) 
 
 
Number of subjects after excluding those who had no 
prescriptions match (315) 
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Figure 2. Source of Prescription Information for Most Common Therapeutic Classes 
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